A new analysis highlights the effectiveness of risankizumab in patients with moderate plaque psoriasis and those newly classified as systemic therapy eligible under International Psoriasis Council ...

These data indicate that "prolonged [TNF inhibitor] treatment plays a protective role in PsA development in severe psoriasis ...

Objective To evaluate the efficacy and safety of an oral selective tyrosine kinase 2 (TYK2) inhibitor, deucravacitinib, in patients with active psoriatic arthritis (PsA). Methods In this double-blind, ...

These findings, which were based on expert opinion of PASI efficacy, mirror ours in that methotrexate, PUV-A, and UV-B were the least costly treatments, followed by cyclosporine and acitretin ...

Meta-analysis of three randomized control trials confirmed that weight loss following lifestyle interventions (diet or physical activity) improves psoriasis compared with reduction in the PASI score ...

Psoriasis is a chronic immune-mediated inflammatory skin disease with a complex etiology and high global burden. Currently, there is no research that emphasizes integrating proteomics data with ...

Although people can be diagnosed with PsA without skin involvement, they will most likely have a family member with skin psoriasis. For example, my mother has psoriasis, my two siblings and I have ...

Bristol Myers BMY announced that the late-stage study on Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA) met its primary endpoint. Sotyktu is an oral, selective tyrosine ...

BMY also presented new data from POETYK PsA-2 study. Results showed superior efficacy of Sotyktu compared with placebo at Week 16. Additionally, through Week 52, clinical responses continued to ...

“Overall, characterization of PRO [patient-reported outcome] measures across the BSA spectrum showed that the burden of psoriasis was similar in patients with low, medium, and high BSA ...

Percentages of patients who reached PASI 75 (FYB202, 97.9%; reference ustekinumab, 96.4%) and PASI 90 (FYB202, 81.7%; reference ustekinumab, 78.2%) at week 28 were similar. Switching from reference ...